Drugs / Liraglutide
Liraglutide price: generic, Victoza and Saxenda
What liraglutide costs without insurance, what pharmacies pay for it, which companies sell the generic, and what happens to Saxenda in 2027. Prices checked Nov 14, 2026; pharmacy costs as of Nov 11, 2026.
Short answer
Generic liraglutide, the Victoza generic, costs $133.58 for a box of 2 pens and $184.41 for a box of 3 pens with TrumpRx.gov's pharmacy coupon; TrumpRx says prices vary by pharmacy. At the label's 1.2 mg or 1.8 mg daily dose, one box lasts 30 days. Pharmacies pay $171.50–$262.69 for that month of generic (NADAC, their average purchase cost). We found no official self-pay price for Victoza or Saxenda, and FDA says Saxenda will be available until it is discontinued in January 2027.1425
Source: TrumpRx.gov, data.medicaid.gov (NADAC) and FDA · checked Nov 14, 2026
One month of liraglutide, by product
| Product | Label daily dose and pens for 30 days | Self-pay price | Pharmacy cost per month (NADAC) |
|---|---|---|---|
| Liraglutide (generic Victoza) Daily injection (pens) | 1.2 or 1.8 mg once daily (same label dosing as Victoza)1617 6 mL (2 pens: 1.2 mg × 30 days = 36 mg) × $28.58316 per mL; 9 mL (3 pens: 1.8 mg × 30 days = 54 mg) × $29.18733 per mL | $133.58–$184.4118 box of 2 pens (30 days at 1.2 mg) / box of 3 pens (30 days at 1.8 mg) | $171.50–$262.6919 |
| Victoza Daily injection (pens) | 1.2 or 1.8 mg once daily202122 6 mL (2 pens: 1.2 mg × 30 days = 36 mg) × $87.75645 per mL; 9 mL (3 pens: 1.8 mg × 30 days = 54 mg) × $87.75209 per mL | No official self-pay listing found (not on TrumpRx.gov). FDA lists it in limited supply. | $526.54–$789.7723 |
| Liraglutide 3 mg (generic Saxenda) Daily injection (pens) | 3 mg once daily (label)2425 15 mL (5 pens: 3 mg × 30 days = 90 mg) × $47.26634 per mL | No official self-pay listing found (the TrumpRx coupon covers only the 2- and 3-pen boxes). | $709.0026 |
| Saxenda Daily injection (pens) | 3 mg once daily (label)2728 15 mL (5 pens: 3 mg × 30 days = 90 mg) × $87.03696 per mL | No official self-pay listing found (not on TrumpRx.gov). FDA: available until discontinuation in January 2027. | $1,305.5529 |
Compare with every other GLP-1: cost per month side by side
The TrumpRx.gov coupon for generic liraglutide
TrumpRx.gov lists generic liraglutide ("Generic for Victoza") as a coupon you show at a retail pharmacy, not as a maker's program. These are the prices in the listing; the pharmacy confirms the final price.1
| Pack | How many | Coupon price | "Original price" (WAC) |
|---|---|---|---|
| Box of 2 Pens, 18mg/3ml (6mL) | 1 | $133.58 | $320.83 |
| Box of 2 Pens, 18mg/3ml (6mL) | 2 | $261.91 | $641.65 |
| Box of 2 Pens, 18mg/3ml (6mL) | 3 | $390.24 | $962.48 |
| Box of 3 Pens, 18mg/3ml (9mL) | 1 | $184.41 | $447.90 |
| Box of 3 Pens, 18mg/3ml (9mL) | 2 | $363.57 | $895.80 |
| Box of 3 Pens, 18mg/3ml (9mL) | 3 | $542.73 | $1,343.70 |
“Prices may vary depending on what the pharmacy has in stock. Call to confirm the final price.”
Which companies sell generic liraglutide
A company is listed here only when FDA's drug listings (the NDC Directory) show a finished package with a marketing start date. An approval without a listed package is not counted as on the market.8 Boxes of 2 or 3 pens are the Victoza generic (1.2 mg or 1.8 mg a day); boxes of 5 pens are the Saxenda generic (3 mg a day).
| FDA application | Companies listing packages | Pens per box | First listed |
|---|---|---|---|
| NDA022341 (authorized generic) | A-S Medication Solutions; Teva Pharmaceuticals USA, Inc. | 2, 3 | 2024-06-24 |
| ANDA215503 | Hikma Pharmaceuticals USA Inc.; Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | 2, 3 | 2024-12-24 |
| ANDA218115 | Meitheal Pharmaceuticals Inc.; NorthStar Rx LLC | 2, 3 | 2025-04-02 |
| ANDA214568 | Teva Pharmaceuticals, Inc. | 5 | 2025-08-28 listing ends 2027-09-30 |
| ANDA215421 | Lupin Pharmaceuticals, Inc. | 2, 3 | 2025-10-02 |
| ANDA217590 | A-S Medication Solutions; Cipla USA Inc.; Orbicular Pharmaceutical Technologies Private Limited | 2, 3 | 2026-01-21 |
| ANDA217234 | Cipla USA Inc.; Orbicular Pharmaceutical Technologies Private Limited | 3, 5 | 2026-02-25 |
| ANDA217063 | Biocon Pharma Inc. | 3, 5 | 2026-03-27 |
| ANDA215245 | Biocon Pharma Inc. | 2, 3 | 2026-04-25 |
Supply: Saxenda ends in January 2027
- Saxenda: FDA's drug shortage list says "Product will be available until discontinuation in January 2027".5
- Teva's 3 mg generic (the Saxenda generic, NDC 0480-7250-46) is listed by FDA as "To Be Discontinued".7 Its package listing ends 2027-09-30.8
- Victoza: FDA lists it with "Limited Availability".6 The generic 2- and 3-pen boxes are listed as available.
What pharmacies pay for generic liraglutide fell 47% in 2026
The NADAC for the generic 2-pen box (NDC 00480366720) went from $54.16 per mL in CMS's first weekly file of 2026 (Jan 7, 2026) to $28.58 per mL from Oct 21, 2026, a change of -47.2%. For one month at 1.2 mg a day (6 mL), that is $324.94 then and $171.50 now, $153.44 less.9
| Rate effective | NADAC per mL | Per month at 1.2 mg (6 mL) |
|---|---|---|
| 2025-12-17 | $54.16 | $324.94 |
| 2026-01-21 | $54.37 | $326.20 |
| 2026-02-18 | $48.74 | $292.47 |
| 2026-03-18 | $43.60 | $261.58 |
| 2026-04-22 | $38.75 | $232.52 |
| 2026-05-20 | $38.60 | $231.59 |
| 2026-06-17 | $37.92 | $227.52 |
| 2026-07-22 | $35.71 | $214.27 |
| 2026-08-19 | $33.82 | $202.91 |
| 2026-09-23 | $31.41 | $188.44 |
| 2026-10-21 | $28.58 | $171.50 |
Citable version of this trend, with the method and data: Pharmacy cost of generic liraglutide fell 47% in 2026 (finding, Nov 14, 2026).
Medicare
- Liraglutide (Victoza, Saxenda, generics) is not on Medicare's negotiated-price lists for 2026 or 2027, or on the list of drugs selected in 2026 for prices starting in 2028.101112
- The $50 Medicare GLP-1 Bridge covers Foundayo, Wegovy and the Zepbound KwikPen; liraglutide is not on its list.13 Medicare GLP-1 coverage
- Medicare Part D plans that list Victoza or generic liraglutide: 1,129 of 5,496 (20.5%) for 202614; 842 of 5,492 (15.3%) for 202715. Saxenda: 0 of 5,496 for 2026; 0 of 5,492 for 2027. By state: Medicare Part D GLP-1 Formulary Coverage by State.
Have insurance? See what your plan's drug list says about generic liraglutide and Saxenda: pick the PDF, get the page to check.
From the FDA labels
Word for word from DailyMed: approved uses, strengths, pack sizes and the dose schedule. Victoza's label is for type 2 diabetes and Saxenda's for weight reduction; the exact approved uses are below.
Victoza
FDA-approved uses · label 1
VICTOZA is indicated:
- •as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus,
- •to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.
Limitations of Use:
VICTOZA contains liraglutide. Coadministration with other liraglutide-containing products is not recommended.
Dosage forms and strengths · label 3
Injection: 18 mg/3 mL (6 mg/mL) clear, colorless solution in a prefilled, single-patient-use pen that delivers doses of 0.6 mg, 1.2 mg, or 1.8 mg.
Dose schedule in the label · label 2.1
Adult Patients
- •The recommended starting dosage of VICTOZA is 0.6 mg injected subcutaneously once daily for one week. The 0.6 mg once daily dosage is intended to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.6), Adverse Reactions (6.1)] during initial titration and is not effective for glycemic control in adults.
- •After one week at the 0.6 mg once daily dosage, increase the dosage to 1.2 mg injected subcutaneously once daily.
- •If additional glycemic control is required, increase the dosage to the maximum recommended dosage of 1.8 mg injected subcutaneously once daily after at least one week of treatment with the 1.2 mg once daily dosage.
Pediatric Patients Aged 10 Years and Older
- •The recommended starting dosage of VICTOZA is 0.6 mg injected subcutaneously once daily.
- •If additional glycemic control is required, increase the dosage in 0.6 mg increments after at least one week on the current dosage, to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.6), Adverse Reactions (6.1)].
- •The maximum recommended dosage is 1.8 mg injected subcutaneously once daily.
How it is supplied (pack sizes) · label 16
How Supplied
VICTOZA Injection: 18 mg/3 mL (6 mg/mL) clear, colorless solution in a prefilled, single-patient-use pen that delivers doses of 0.6 mg, 1.2 mg, or 1.8 mg is available in the following package sizes:
2 x VICTOZA pen NDC 0169-4060-12
3 x VICTOZA pen NDC 0169-4060-13
Recommended Storage
Prior to first use, VICTOZA should be stored in a refrigerator between 36ºF to 46ºF (2ºC to 8ºC). Do not store in the freezer or directly adjacent to the refrigerator cooling element. Do not freeze VICTOZA and do not use VICTOZA if it has been frozen.
After first use of the VICTOZA pen, the pen can be stored for 30 days at controlled room temperature 59°F to 86°F (15°C to 30°C) or in a refrigerator 36°F to 46°F (2°C to 8°C). Keep the pen cap on when not in use. Protect VICTOZA from excessive heat and sunlight. Always remove and safely discard the needle after each injection and store the VICTOZA pen without an injection needle attached. This will reduce the potential for contamination, infection, and leakage while also ensuring dosing accuracy. Always use a new needle for each injection to prevent contamination.
Saxenda
FDA-approved uses · label 1
SAXENDA is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in:
- • Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity.
- • Adults with overweight in the presence of at least one weight-related comorbid condition.
Limitations of Use
- • SAXENDA contains liraglutide. Coadministration with other liraglutide-containing products or with any other glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.
- • The safety and effectiveness of SAXENDA in pediatric patients with type 2 diabetes have not been established.
Dosage forms and strengths · label 3
Injection: 6 mg/mL clear, colorless solution in a 3 mL prefilled, single-patient-use pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg.
Dose schedule in the label · label 2.2
- •Initiate SAXENDA with a dose of 0.6 mg daily for one week. Then follow the dosage escalation schedule in Table 1 to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.7), Adverse Reactions (6.1)].
Table 1. Dosage Escalation Schedule
Week | Daily Dose |
1 | 0.6 mg |
2 | 1.2 mg |
3 | 1.8 mg |
4 | 2.4 mg |
5 and onward | 3 mg |
- Adult Patients
- •For adults, the recommended dosage of SAXENDA is 3 mg daily, lower dosages are for titration only.
- •Discontinue SAXENDA if the patient cannot tolerate the 3 mg dosage.
- •If patients do not tolerate an increased dose during dosage escalation, consider delaying dosage escalation for approximately one additional week.
- •Evaluate the change in body weight 16 weeks after initiating SAXENDA and discontinue SAXENDA if the patient has not lost at least 4% of baseline body weight, since it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment.
- •In adult patients with type 2 diabetes, monitor blood glucose prior to starting SAXENDA and during SAXENDA treatment.
Pediatric Patients
- •For pediatric patients, the recommended maintenance dosage of SAXENDA is 3 mg daily. Pediatric patients who do not tolerate 3 mg daily may have their maintenance dose reduced to 2.4 mg daily. Discontinue SAXENDA if the patient cannot tolerate the 2.4 mg dose.
- •If pediatric patients do not tolerate an increased dose during dosage escalation, the dose may also be lowered to the previous level. Dosage escalation for pediatric patients may take up to 8 weeks.
- •Evaluate the change in BMI after 12 weeks on the maintenance dose and discontinue SAXENDA if the patient has not had a reduction in BMI of at least 1% from baseline, since it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment.
How it is supplied (pack sizes) · label 16
How Supplied
SAXENDA injection: 6 mg/mL clear, colorless solution in a 3 mL single-patient-use prefilled pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg or 3 mg is available in the following package sizes:
3 x SAXENDA pen NDC 0169-2800-13
5 x SAXENDA pen NDC 0169-2800-15
Recommended Storage
Prior to first use, SAXENDA should be stored in a refrigerator between 36ºF to 46ºF (2ºC to 8ºC). Do not store in the freezer or directly adjacent to the refrigerator cooling element. Do not freeze SAXENDA and do not use SAXENDA if it has been frozen.
After initial use of the SAXENDA pen, the pen can be stored for 30 days at controlled room temperature 59°F to 86°F (15°C to 30°C) or in a refrigerator 36°F to 46°F (2°C to 8°C). Keep the pen cap on when not in use. Protect SAXENDA from excessive heat and sunlight. Always remove and safely discard the needle after each injection and store the SAXENDA pen without an injection needle attached. This will reduce the potential for contamination, infection, and leakage while also ensuring dosing accuracy.
How this page is kept current
- Makers' self-pay listings on TrumpRx.gov: archived weekly (Mondays). A new dated copy is saved only when a listing changes, so a price's "as of" date is the copy it comes from.
- NADAC (CMS's survey of what pharmacies pay): CMS publishes a new file weekly; we archive it daily from data.medicaid.gov.
- FDA labels (DailyMed, openFDA), the NDC Directory and the drug shortage list: archived daily.
- Every change in an archived copy is flagged for a person to check against the official page; the site is updated only after that check. Nothing is published automatically. Changes: price change log · mistakes: corrections · all sources: sources and update schedule.
Which drug, which dose, and whether to start, stop or switch are medical decisions. Ask your doctor or pharmacist.
Official sources for this page (29)
“Prices may vary depending on what the pharmacy has in stock. Call to confirm the final price.”
TrumpRx.gov: Liraglutide (Generic for Victoza) (pharmacy coupon) · as of Nov 14, 2026“LIRAGLUTIDE 2-PAK 18 MG/3 ML: 28.58316 per ML, effective 2026-10-21”
“2 x Liraglutide Injection pen NDC 0143-9144-02 3 x Liraglutide Injection pen NDC 0143-9144-03”
FDA label (DailyMed): liraglutide injection (Hikma), version 7 · as of Nov 14, 2026“Initiate at 0.6 mg injected subcutaneously once daily for one week then increase to 1.2 mg daily. If additional glycemic control is required, increase the dose to 1.8 mg daily”
FDA label (DailyMed): Victoza, version 31 · as of Nov 14, 2026“Product will be available until discontinuation in January 2027”
“Limited Availability”
“To Be Discontinued”
- FDA NDC Directory (openFDA): liraglutide finished products · as of Nov 14, 2026
- data.medicaid.gov: NADAC 2026, all weekly files for NDC 00480366720 · as of Nov 14, 2026
- CMS: negotiated prices, 2026 · as of Oct 23, 2026
- CMS: negotiated prices, 2027 · as of Oct 23, 2026
- CMS: drugs selected for negotiation, prices from 2028 · as of Oct 25, 2026
“Starting July 1, 2026, Medicare covers these GLP-1 drugs: Foundayo® (tablet) Wegovy® (injection or tablet) Zepbound® (KwikPen® only. The program doesn’t cover single-dose Zepbound® vials or pens).”
Medicare.gov: Weight loss drugs · as of Nov 5, 2026“2 x Liraglutide Injection pen NDC 0143-9144-02 3 x Liraglutide Injection pen NDC 0143-9144-03”
FDA label (DailyMed): liraglutide injection (Hikma), version 7 · as of Nov 14, 2026“Initiate at 0.6 mg injected subcutaneously once daily for one week then increase to 1.2 mg daily. If additional glycemic control is required, increase the dose to 1.8 mg daily”
FDA label (DailyMed): Victoza, version 31 · as of Nov 14, 2026“Prices may vary depending on what the pharmacy has in stock. Call to confirm the final price.”
TrumpRx.gov: Liraglutide (Generic for Victoza) (pharmacy coupon) · as of Nov 14, 2026“LIRAGLUTIDE 2-PAK 18 MG/3 ML: 28.58316 per ML, effective 2026-10-21”
“Initiate at 0.6 mg injected subcutaneously once daily for one week then increase to 1.2 mg daily. If additional glycemic control is required, increase the dose to 1.8 mg daily”
FDA label (DailyMed): Victoza, version 31 · as of Nov 14, 2026“18 mg/3 mL (6 mg/mL)”
FDA label (DailyMed): Victoza, version 31 · as of Nov 14, 2026“2 x VICTOZA pen NDC 0169-4060-12 3 x VICTOZA pen NDC 0169-4060-13”
FDA label (DailyMed): Victoza, version 31 · as of Nov 14, 2026“VICTOZA 2-PAK 18 MG/3 ML PEN: 87.75645 per ML, effective 2026-10-21”
“The recommended dose of liraglutide injection is 3 mg daily.”
FDA label (DailyMed): liraglutide injection 3 mg (Teva), version 4 · as of Nov 14, 2026“5 x liraglutide injection pen NDC 0480-7250-46”
FDA label (DailyMed): liraglutide injection 3 mg (Teva), version 4 · as of Nov 14, 2026“LIRAGLUTIDE 5-PAK 18 MG/3 ML: 47.26634 per ML, effective 2026-10-21”
“The recommended dose of SAXENDA is 3 mg daily.”
FDA label (DailyMed): Saxenda, version 22 · as of Oct 17, 2026“5 x SAXENDA pen NDC 0169-2800-15”
FDA label (DailyMed): Saxenda, version 22 · as of Oct 17, 2026“SAXENDA 18 MG/3 ML PEN: 87.03696 per ML, effective 2026-10-21”